SCHEMBL527616

SCHEMBL527616

CN(C)CC([NH])Cc1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 2/20 0.48
HRH1 P35367 1/20 0.48
TDP1 Q9NUW8 1/20 0.47
ALDH1A1 P00352 1/20 0.46
TSHR P16473 1/20 0.46
SLC6A2 P23975 3/20 0.46
SLC6A4 P31645 2/20 0.46
SLC6A3 Q01959 2/20 0.46
ADRA2B P18089 1/20 0.46
ADRA2C P18825 1/20 0.46
ADRA1A P35348 1/20 0.46
OPRK1 P41145 1/20 0.46
KCNH2 Q12809 1/20 0.46
TAAR1 Q96RJ0 5/20 0.43
SIGMAR1 Q99720 4/20 0.43
MAOA P21397 4/20 0.43
CYP2A6 P11509 1/20 0.43
ADORA2A P29274 1/20 0.43
ADORA1 P30542 1/20 0.43
MAOB P27338 3/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4469506 0.79 EPHX1 (0.55) SLC6A2SLC6A4SLC6A3TAAR1SIGMAR1
SCHEMBL7164865 0.78 HTR2A (0.52) HTR2AHRH1TDP1ALDH1A1TSHR
SCHEMBL14292431 0.77 SIGMAR1 (0.53) HTR2AHRH1TDP1ALDH1A1TSHR
SCHEMBL555264 0.77 SIGMAR1 (0.53) HTR2AHRH1TDP1ALDH1A1TSHR
SCHEMBL172909 0.75 EPHX1 (0.64) HTR2AHRH1TDP1ALDH1A1TSHR
SCHEMBL13060807 0.75 OPRK1 (0.55) HTR2AHRH1TDP1ALDH1A1TSHR
SCHEMBL172932 0.75 EPHX1 (0.64) HTR2AHRH1TDP1ALDH1A1TSHR
SCHEMBL1205954 0.75 HTR2A (0.48) HTR2AHRH1TDP1ALDH1A1TSHR
SCHEMBL1205950 0.75 HTR2A (0.48) HTR2AHRH1TDP1ALDH1A1TSHR
SCHEMBL6274651 0.75 OPRK1 (0.55) HTR2AHRH1TDP1ALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7026324-B2 Thrombin inhibitors MERCK & CO., INC. (US) 2006-04-11 US disclosed
US-20040097730-A1 Thrombin inhibitors MERCK & CO., INC. 2004-05-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040097730-A1 Thrombin inhibitors F3, F2, SERPINC1 HTR2A 2718/4885HRH1 1093/4885TDP1 2827/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.